Selective GHS-R1a agonist releasing growth hormone with little effect on cortisol or prolactin.
What was measuredThe receptor pharmacology is reliable and well characterised. That is a mechanism, not a clinical benefit.
Also known as NNC 26-0161
Taken into human trials and did not outperform placebo on its primary endpoint, or development was discontinued. This is stronger evidence than "untested" — it is evidence of absence, not absence of evidence.
A selective growth hormone secretagogue receptor agonist, developed by Novo Nordisk and later taken into trials for a gastrointestinal indication rather than anything related to body composition.
Selective GHS-R1a agonist. Its selectivity — stimulating growth hormone release with little effect on cortisol or prolactin — is what made it useful as a research tool.
Tested for postoperative ileus, it failed to show benefit on the primary endpoint and development was discontinued. This is a human result, and a negative one.
Its selectivity at GHS-R1a is well characterised, which is why it remains a standard comparator in endocrine research.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Not approved anywhere. Development discontinued after a failed phase 2 trial.
The sites below are where Ipamorelin is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
Selective GHS-R1a agonist releasing growth hormone with little effect on cortisol or prolactin.
What was measuredThe receptor pharmacology is reliable and well characterised. That is a mechanism, not a clinical benefit.
Trialled to shorten recovery of bowel function after surgery.
What was measuredThe phase 2 trial in postoperative ileus did not meet its primary endpoint. Development for the indication stopped.
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.